Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1699-3055
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer ; day:12 ; month:2 ; year:2020 ; pages:1-14
Clinical and translational oncology ; (12.2.2020), 1-14

Creator
Alvarez-Lopez, I.
Bezares, S.
Dalmau Portulas, E.
García-Martínez, E.
García-Sáenz, J. Á
Gil-Gil, M.
Martínez de Dueñas, E.
Ribelles, N.
Santaballa Bertrán, A.
Contributor
SpringerLink (Online service)

DOI
10.1007/s12094-019-02269-7
URN
urn:nbn:de:101:1-2020050920561762318348
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Alvarez-Lopez, I.
  • Bezares, S.
  • Dalmau Portulas, E.
  • García-Martínez, E.
  • García-Sáenz, J. Á
  • Gil-Gil, M.
  • Martínez de Dueñas, E.
  • Ribelles, N.
  • Santaballa Bertrán, A.
  • SpringerLink (Online service)

Other Objects (12)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

Prognostic factors after isolated ipsilateral local and regional recurrence in HER2-negative luminal breast cancer: a multi-center retrospective study

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Related objects